Skip to main content
OpenTrials
Completed

NCT Number: NCT06644482

Exercise as Treatment for Patients With Inclusion Body Myositis

There is little knowledge about exercise for patients with inclusion body myositis (IBM). Patients with IBM have limited access to rehabilitation and physiotherapy resources, despite a significant need for these services due to the progressive nature of the condition, which leads to a gradual decline in physical function. The purpose of the project is to develop and implement a 16-week exercise intervention at Oslo University Hospital (OUS) for patients with IBM living in Oslo and the surrounding area. The exercise sessions will take place once a week at OUS, under the guidance of physiotherapists with extensive clinical experience with this patient group. Patients are encouraged to exercise at home at least once a week between sessions at OUS to achieve sufficient amount of exercise that normally will improve physical fitness. The feasibility and benefits of the exercise intervention will be evaluated using various methods, such as focus group interviews, physical tests, and questionnaires. The study will also provide valuable insight into whether exercise can lead to improvements in muscle strength, fitness, and balance in patients with IBM.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Oslo University Hospital

Oslo, 0424, Norway

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • IBM diagnosis
  • Able to walk with aids

Exclusion criteria

-Unable to understand and write Norwegian

Treatment and study plan

Exercise group in a hospital setting

Other

Participants will exercise in a group once a week for 16 weeks in a hospital setting.

Primary outcomes

  1. Feasibility: proportion completing the exercise intervention

    Time frame: Baseline to 16 week

    Proportion of included participants completing the exercise intervention

  2. Feasibility: proportion of received exercise diaries

    Time frame: Baseline to 16 weeks

    Proportion of received exercise diaries (0-16 per participant)

  3. Recruitment: proportion enrolled

    Time frame: Baseline

    Proportion of eligible patients enrolled

  4. Feasibility: exercise diaries

    Time frame: Baseline to 16 week

    The participants will log experiences with the intervention (e.g. completed/not completed exercises, reasons for any non-completion, other training activities, barriers/facilitators).

  5. Feasibility: proportion of patients completing physical fitness tests

    Time frame: Baseline and 17 weeks

    Proportion of patients completing physical fitness tests

  6. Feasibilty: Focus group interview

    Time frame: 17 weeks

    Participants will participate in focus group interviews exploring the experiences of the intervention

Secondary outcomes

  1. Changes in walking distance

    Time frame: Baseline and 17 weeks

    Assessed by the 2 minutes walking test. Changes in walking distance measured as meters.

  2. Changes in functional lower extremity strength

    Time frame: Baseline and 17 weeks

    The patients are to stand up and sit down from a chair as many times as they can within 30 seconds, and the total number of times is recorded.

  3. Changes in muscle endurance

    Time frame: Baseline and 17 weeks

    Assessed by the Functional Index- 2 in three muscle groups; shoulder flexors (maximum 60 repetitions), neck flexors (maximum 30 repetitions) and hip flexors (maximum 60 repetitions).

  4. Changes in muscle strength

    Time frame: Baseline and 17 weeks

    Assessed by the Manual Muscle test - 8 (MMT - 8), which includes unilateral testing of muscle strength in 8 eight muscle groups; (Deltoid, Biceps, Wrist extensors, Quadriceps, Ankle dorsiflexors, Neck flexors, Gluteus medius and Gluteus maximux). Each muscle group is scored on a 0-10-point scale (10=best score). The total MMT - 8 will be calculated (0-80, 80=best score).

  5. Changes in grip stength

    Time frame: Baseline and 17 weeks

    Assessed by hydraulic hand dynamometer (Baseline). Change in grip strength is recorded in kilograms.

  6. Change in the Berg Balance Scale

    Time frame: Baseline and 17 weeks

    The Berg Balance Scale (BBS) is a 14-item objective measure that assesses static and dynamic balance and fall risk in adults. Each item is scored on a 5-point ordinal scale ranging from 0 to 4, with 0 indicating an inability to complete the task entirely and 4 indicating an ability to complete the task criterion.The total score ranges from 0-52 (52 indicates best score).

  7. Change in the Inclusion Body Myositis Functional Rating Scale (IBMFRS)

    Time frame: Baseline and 17 weeks

    The IBMFRS consists of 10 questions about a patient's ability to perform daily activities (including walking, dressing, swallowing and handling utensils). Each question is answered using a number from 0-4. The numbers are added up to give the total score ranging from 0 to 40, with 40 being the best possible score

  8. Change in the Health Assessment Questionnaire (HAQ) score

    Time frame: Baseline and 17 weeks

    Change in the last week disability on the total HAQ score (0-3, 0 indicates best possible function). The HAQ comprises 30 questions, covering eight functional ability domains related to daily living during the past week (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities). The score ranges from 0-3 (0 indicates no disability, 3 indicates severe disability) in each domain, of which the total CHAQ is calculated.

  9. Change in Patient Specific Functional Scale (PSFS)

    Time frame: Baseline and 17 weeks

    The patients will identify 3-5 important activities they are unable to perform or have difficulty with due to inclusion body myositis. The patients are then asked to rate the current level of difficulty associated with each activity on an 11-point scale, from 0 (not able to perform the activity) to 10 (no problems).

  10. Change in self-reported physical activity

    Time frame: Baseline and 17 weeks

    Assessed by the International Physical Activity Questionnaire-Short form (IPAQ-SF). Change in time (minutes per week/day) and Metabolic Equivalent of Task (MET-minutes per week/day) spent on sitting, walking, and moderate- and vigorous intensity physical activity the last week. METs are calculated by using the corresponding MET-values for walking (3.3 MET), and moderate-(4.0 MET) and vigorous (8.0 MET) intensity physical activity.

  11. Change in Health-Related Quality of Life

    Time frame: Baseline and 17 weeks

    Assessed by the Short Form Health Survey (SF36) which comprises 36 questions covering the areas of physical function, role limitations (physical), pain, general health perception, energy and fatigue (vitality), social function, role limitations (emotional), and mental health. The results are recoded so that the final score for each area ranges from 0 to 100, where 100 indicates the best possible health.

Other outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety].

    Time frame: Baseline to 16 week

    Patients will log 1) total of falls during the training period and 2) total number of near-falls during the training period.

  2. Incidence of Treatment-Emergent Adverse Events [Tolerability]- pain.

    Time frame: Baseline to 16 week

    Self-reported pain will be assessed by numeric rating scale ranging from 0 (no pain) to 10 (worst pain)

  3. Incidence of Treatment-Emergent Adverse Events [Tolerability]- muscle fatigue

    Time frame: Baseline to 16 week

    Self-reported muscle fatigue will be assessed by numeric rating scale ranging from 0 (no muscle fatigue) to 10 (worst muscle fatigue)

  4. Incidence of Treatment-Emergent Adverse Events [Tolerability]- muscle fatigue

    Time frame: Baseline to 16 week

    Self-reported muscle soreness will be assessed by numeric rating scale ranging from 0 (no muscle soreness) to 10 (worst muscle soreness)

  5. Incidence of Treatment-Emergent Adverse Events [Tolerability]- fatigue

    Time frame: Baseline to 16 week

    Self-reported fatigue will be assessed by numeric rating scale ranging from 0 (no fatigue) to 10 (worst fatigue)

Sponsors and collaborators

Lead sponsor

Oslo University Hospital

Other

Collaborators

  • The Dam Foundation
  • The Norwegian Rheumatism Association

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Oct 16, 2024
Registry last updated
Jun 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.